Leukemia (Pediatric) Clinical Trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL0932&rank=1

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00408005?term=AALL0434&rank=2

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01142427?term=AALL08B1&rank=1

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01406756?term=AALL1131&rank=1

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00557193?term=AALL0631&rank=1

1.0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 1.1 Primary Aims 1.1.1 To evaluate the feasibility and toxicity of using bortezomib in combination with the ALL R3 re-induction regimen in pediatric patients with relapsed or refractory ALL or LL. 1.1.2 To determine the rate of complete response and negative minimal residual disease ...

This is a Phase 1 study with ADCT-301 to evaluate the safety, tolerability and pharmacokinetics of ADCT-301 in patients with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). ADCT-301 is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen ...

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.